Key Highlights

  • Liquidia (NASDAQ:LQDA) traded at USD 46.06 in a published market data snapshot on November 5, 2026, up 64.79% over one month and 9.56% over six months, after a 2.79% slide in the latest session.
  • The one month gain ranks third among mid caps with market values of USD 2 billion to USD 10 billion, yet the three month change is still down 48.79% and the one week change is down 0.37%.
  • On October 14, 2026 the company settled all six lawsuits with United Therapeutics, keeping YUTREPIA on the market for PAH, with net payments of about USD 380.7 million through April 2027.
  • Preliminary third quarter YUTREPIA sales reached USD 222.7 million, up from USD 170.4 million in the second quarter, and cash stood at USD 396.1 million at September 30, 2026.

A Court Ruling Erased Gains Before the Settlement Recovery

The one month climb is partly a rebound from a legal shock. On September 30, 2026, a Delaware court found that YUTREPIA infringed two claims of a United Therapeutics Patent covering inhaled treprostinil for PH-ILD, and found four other asserted claims invalid. The shares dropped about 57% that day and roughly 14% more the next session, to near USD 26.60. Simple arithmetic on the snapshot (calculated) places the price roughly a month earlier near USD 27.95, so the 64.79% gain largely retraces that slide. The stock was near USD 37 on October 14, 2026, when the settlement was announced, a gain of about 40% on the day.

Settlement Terms Remove the Overhang and Narrow the Label

The settlement ends all six pending suits, covering patent, trade secret, contract and antitrust claims, and removes an open-ended injunction risk. Liquidia must drop the PH-ILD indication from its label and stop promoting it, but may keep selling for PAH. Management expects to fund the payments from cash and revenue, with an initial USD 175 million due within 30 Business days. Analyst reactions were mixed: one brokerage upgraded the shares to Buy with a USD 70 target, a second moved to Outperform with USD 59, a third trimmed its target to USD 58 from USD 72, and a fourth lifted its target to USD 33 from USD 30.

Second Quarter Earnings Base, Cash Outflow and Pipeline Legal Risks

Second quarter total Revenue was USD 171.7 million, with Net Income of USD 74.7 million, or USD 0.74 diluted, and cash of USD 284.2 million at June 30, 2026. The six month change of 9.56% and the three month change of down 48.79% show the stock still sits far below its pre-ruling level. Risks include the USD 380.7 million cash outflow, a possible appeal, loss of the PH-ILD label and legal questions around the L606 pipeline. Liquidia's Market Value was not verified in the material. A Mid cap stock can swing on a handful of large trades, and a rebound this size can reverse. Year to date performance was not visible in the snapshot.

Where Things Stand

Liquidia (NASDAQ:LQDA) rose 64.79% in a month because a settlement with United Therapeutics cleared a legal overhang that followed a September 30 court loss, with strong preliminary YUTREPIA sales and mixed analyst moves adding support. It ranks third among mid caps on the one month list in the snapshot taken November 5, 2026. The down 48.79% three month change shows the round trip is incomplete, and the stock fell 2.79% in the latest session. This is context, not a forecast.